A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial

Fox, Christopher P.; Ali, Ayesha S.; McIlroy, Graham; Thust, Steffi; Martinez-Calle, Nicolás; Jackson, Aimee E.; Hopkins, Louise M.; Thomas, Catherine M.; Kassam, Shireen; Wright, Josh; Chaganti, Sridhar; Smith, Jeffery; Chau, Ian; Culligan, Dominic; Linton, Kim M.; Collins, Graham P.; Ferreri, Andrés J. M.; Lewis, David; Davies, Andrew J.; Johnson, Rod; Auer, Dorothee P.; Cwynarski, Kate

doi:10.1182/bloodadvances.2021004779

All Outputs (2)

Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy (2023)
Journal Article

Primary Central Nervous System Lymphoma (PCNSL) is a highly malignant brain tumour. We investigated dynamic changes in tumour volume and apparent diffusion coefficient (ADC) measurements for predicting outcome following treatment with MATRix chemothe... Read More about Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix Immunochemotherapy.

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial (2021)
Journal Article

Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a multicenter phase 1/2 study... Read More about A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.